Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040014/S051

Ampere Generator

Irvine Biomedical, Inc. · Decision date Aug 7, 2026

FDA DECISIONP040014/S051

What did the FDA approve?

FDA records P040014/S051 as a supplement to PMA P040014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 7, 2026.

FDA approval order statement

approval for firmware changes to the TactiSys Quartz Equipment v1.8.0 and Ampere Generator v1.2.0 to maintain compatibility with the TactiFlex Duo Ablation Catheter, Sensor Enabled
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Aug 7, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P040014/S051
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
APPR
Decision date
Aug 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

For the original device and its historical approval scope, see PMA P040014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040014 · Original PMA

    IBI THERAPY CARDIAC ABLATION SYSTEM ERS/ 1500T RF GENERATOR

  2. P040014/S051 received

    Application receipt date recorded by FDA.

  3. P040014/S051 · FDA decision

    Real-Time Process

  4. P040014/S052 · Related supplement

    Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter

Timeline entries are records held by MedtechLedger for P040014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040014

Product / regulatory recordCompanyPathwayDecision dateSource
Irvine Biomedical, Inc.PMA approvalJan 14, 2005FDA
Irvine Biomedical, Inc.PMA supplementSep 3, 2026FDA

Explore the linked device profile

Other records with product code LPB

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Ampere GeneratorP960016/S094
St Jude MedicalPMA supplementAug 7, 2026FDA
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA
Medtronic Cryocath, LPPMA supplementApr 23, 2026FDA
Livewire TC XLSP960016/S093
St Jude MedicalPMA supplementJan 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Irvine Biomedical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2375 Morse Ave., Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records